Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

More articles from Preclinical Probes for Oncology

  • You have access
    Development of 43Sc/47Sc-PSMA-617 as Theranostics for Prostate Cancer: Preliminary Cellular and Animal Studies
    Jason Meier, Mohammed Bhuiyan, Hannah Zhang, Hsiu-Ming Tsai, Lucas Berens, Lara Leoni, Megan Mendez, Phillip Selman, Pavithra Kankanamalage, Thomas Brossard, Brittany Broder, Amy Renne, Matt Gott, John Greene, Jerry Nolen, Richard Freifelder, Walter Stadler, Ralph Weichselbaum, Chien-Min Kao, David Rotsch, Russell Szmulewitz and Chin-Tu Chen
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2895;
  • You have access
    Establishment of efficacy of DOTA-based pretargeted radioimmunotherapy with a bivalent radiohapten for enhanced therapeutic indices
    Brett Vaughn, Darren Veach, Daniela Burnes Vargas, Shin Seo, Blesida Punzalan, Pat Zanzonico, Hong Xu, Hong-fen Guo, Guangbin Yang, Ouathek Ouerfelli, Nai-Kong Cheung, Steven Larson and Sarah Cheal
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2881;
  • You have access
    TAM Targeted Imaging Agents Binding CD206 and Selective Blocking of Off Target Liver Localization
    Jennifer Bartels, Solana Fernandez, Jeffrey Arnold, Grace O'Malley, David Ralph and Suzanne Lapi
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2862;
  • You have access
    A Novel approach for ovarian cancer detection
    Sushil Tripathi and Mathew Thakur
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2889;
  • You have access
    Formulation and preclinical analysis of 68Ga/177Lu/225Ac labeled αvβ3-integrin targeting peptidomimetic (IAC) for PET Imaging and targeted radionuclide therapy
    Somit Pandey, JAYA SHUKLA, Gurvinder Gill, Rakhee Vatsa, Imraan Rather, Vijayta Chadha and STANLEY SATZ
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2879;
  • You have access
    Developing a new 18F-labeled peptide for PET imaging of GPC3 expression in hepatocellular carcinoma
    Quan Chen, Xiaoyun Zhou, Juno Van Valkenburgh, Peter Conti and Kai Chen
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2459;
  • You have access
    Radiochemistry, biodistribution and imaging study of 161Tb and 155Tb labeled crown-αMSH for MC1R targeting theranostics
    Luke Wharton, Scott McNeil, Gokce Engudar, Chengcheng Zhang, Michiel Van de Voorde, Maarten Ooms, Peter Kunz, Francois Benard, Valery Radchenko and Hua Yang
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2356;
  • You have access
    PET imaging of a modified anti-PD-L1 probe 68Ga-BMS-986192 in immunocompetent mice and non-human primates
    Huimin Zhou and Xiaohua Zhu
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2306;
  • You have access
    124I-Labeled Antibody Fragments for Non-invasive Evaluation of Tumour PD-L1 expression In Vivo
    Yuan Cheng, Dai Shi, Zhan Xu, Zhan Si, Qingyu Lin, Fu Zhequan, Hongcheng Shi and Dengfeng Cheng
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2452;
  • You have access
    GPC3-targeted ImmunoPET Imaging of Hepatocellular Carcinomas
    Shuxian An, Jianjun Liu and Weijun Wei
    Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2479;

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
SNMMI

© 2025 SNMMI

Powered by HighWire